Orexo

Board/Management Information • Oct 17, 2025

OREXO´S NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026

Uppsala, Sweden – October 17, 2025 – The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 7, 2026, have been appointed and comprises of the following members:

• Henrik Kjaer Hansen, (Chairman, appointed by Novo Holdings A/S)
• Claus Berner Møller, (appointed by The Danish Labour Market Supplementary Pension, ATP)
• Stefan Hansson, (private investor)
• Friedrich von Bohlen, (Chairman of the Board of Orexo).

The appointments have been made in accordance with the rules last approved by Orexo´s AGM. The Nomination Committee represents approximately 34 percent of the number of votes in the company as end of August 2025.

Shareholders who want to submit proposals to the Nomination Committee can do this by sending an e-mail to ir@orexo.com (subject "Nomination Committee") at latest March 2, 2026.

Orexo AB (publ.)

Lena Wange, IR & Communications Director

Tel: +46 (0)18 780 88 00

E-mail: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs on OTCQX market (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

Attachments

Orexo´s Nomination Committee for the Annual General Meeting 2026